1. by Deborah M. Stephens, and John C. Byrd
How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia
by Deborah M. Stephens, and John C. Byrd
Blood
Volume 133(12):
March 21, 2019
©2019 by American Society of Hematology

2. Proposed mechanisms for ibrutinib-related adverse events.
Deborah M. Stephens, and John C. Byrd Blood 2019;133:
©2019 by American Society of Hematology

3. Management of atrial fibrillation in patients treated with ibrutinib
Management of atrial fibrillation in patients treated with ibrutinib. *Notable drug interactions with ibrutinib include diltiazem, verapamil, and amiodarone (CYP3A4 inhibitors) and amiodarone (P-glycoprotein). #1 point each for a history of congestive heart...
Management of atrial fibrillation in patients treated with ibrutinib. *Notable drug interactions with ibrutinib include diltiazem, verapamil, and amiodarone (CYP3A4 inhibitors) and amiodarone (P-glycoprotein). #1 point each for a history of congestive heart failure, hypertension, diabetes mellitus, or vascular disease, age 65 to 74 years, or female sex and 2 points each for age ≥75 years or a history of stroke. $Discuss risk of thromboembolic events with patient. ^Possible options include venetoclax with or without rituximab, idelalisib, and duvelisib.
Deborah M. Stephens, and John C. Byrd Blood 2019;133:
©2019 by American Society of Hematology